ERBB2 and breast cancer: The addition of pertuzumab (a humanized monoclonal antibody targeting an epitope of HER2 different from the one targeted by trastuzumab) to trastuzumab associated with docetaxel has been shown to yield higher rates of pCR, and a higher five-year DFS, in early, locally advanced and inflammatory BC [46,47].